Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4

Full text
Author(s):
Show less -
Pinheiro, Celine [1, 2] ; Miranda-Goncalves, Vera [3, 4] ; Longatto-Filho, Adhemar [4, 1, 3, 5] ; Vicente, Anna L. S. A. [1] ; Berardinelli, Gustavo N. [1] ; Scapulatempo-Neto, Cristovam [6] ; Costa, Ricardo F. A. [2] ; Viana, Cristiano R. [6] ; Reis, Rui M. [4, 1, 3] ; Baltazar, Fatima [4, 3] ; Vazquez, Vinicius L. [1, 7]
Total Authors: 11
Affiliation:
[1] Barretos Canc Hosp, Mol Oncol Res Ctr, Sao Paulo - Brazil
[2] Dr Paulo Prata FACISB, Barretos Sch Hlth Sci, Sao Paulo - Brazil
[3] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Hlth Sci, Braga - Portugal
[4] ICVS 3Bs PT Govt Associate Lab, Braga - Portugal
[5] Univ Sao Paulo, Sch Med, Lab Med Invest LIM 14, Sao Paulo - Brazil
[6] Barretos Canc Hosp, Dept Pathol, Sao Paulo - Brazil
[7] Barretos Canc Hosp, Dept Surg, Melanoma Sarcoma, Sao Paulo - Brazil
Total Affiliations: 7
Document type: Journal article
Source: CELL CYCLE; v. 15, n. 11, p. 1462-1470, 2016.
Web of Science Citations: 14
Abstract

BRAF mutations are known drivers of melanoma development and, recently, were also described as players in the Warburg effect, while this reprogramming of energy metabolism has been identified as a possible strategy for treating melanoma patients. Therefore, the aim of this work was to evaluate the expression and prognostic value of a panel of glycolytic metabolism-related proteins in a series of melanomas. The immunohistochemical expression of MCT1, MCT4, GLUT1, and CAIX was evaluated in 356 patients presenting melanoma and 20 patients presenting benign nevi. Samples included 20 benign nevi, 282 primary melanomas, 117 lymph node and 54 distant metastases samples. BRAF mutation was observed in 29/92 (31.5%) melanoma patients and 17/20 (85%) benign nevi samples. NRAS mutation was observed in 4/36 (11.1%) melanoma patients and 1/19 (5.3%) benign nevi samples. MCT4 and GLUT1 expression was significantly increased in metastatic samples, and MCT1, MCT4 and GLUT1 were significantly associated with poor prognostic variables. Importantly, MCT1 and MCT4 were associated with shorter overall survival. In conclusion, the present study brings new insights on metabolic aspects of melanoma, paving the way for the development of new-targeted therapies. (AU)

FAPESP's process: 15/25351-6 - MCT1 as a target and response mediator in melanoma therapy
Grantee:Céline Marques Pinheiro
Support type: Research Grants - Young Investigators Grants
FAPESP's process: 12/04194-1 - The biologic and clinical characterization of the RAS-MAPK and PI3K-AKT pathways in cutaneous and mucosal melanomas among Brazilians and comparison with patients of the United States of America
Grantee:Vinicius de Lima Vazquez
Support type: Regular Research Grants